‘Pop into the labs of Manchester biotech C4X Discovery and you could be in for a surprise. Instead of scientists perched at their work stations peering down microscopes or poring over data, you might find them walking around, arms outstretched, holding what would appear to be imaginary objects.
These scientists haven’t gone mad. They’re pioneers of a new field in drug discovery that combines science with the sort of virtual reality technology typically associated with gaming. Using a headset and hand controls they’re transported into 3D chambers where they can access a database of virtual molecules to pull and twist to see how they fit together.’
5 October 18 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that at the General Meeting held earlier today in connection with the Company’s Placing and Open Offer at a price of 90 pence per new Ordinary Share, details of which were announced on 18 September 2018, all resolutions put to shareholders were duly passed.
Proceeds of fundraise will support the Company’s strategy of becoming the world’s most productive, self-sustaining drug discovery engine
18 September 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces a proposed conditional Placing of Placing Shares with existing and new institutional investors to raise up to approximately £10.0 million before expenses at the Issue Price of 90 pence per new Ordinary Share.
As a leading innovator of research, discovery, and development in the pharmaceutical industry, C4X Discovery is on a quest to uncover and design new drugs that could have a huge impact on the healthcare world in the years to come. While the process of taking a new drug from concept to market typically moves along at a slow, methodical pace, the team at C4X has found Unreal Engine is the perfect catalyst for unlocking the path forward in faster, more immersive ways.
Grant awarded to investigate efficacy of C4X3256 in preclinical models of cocaine addiction, further demonstrating the efficacy of C4X3256 across broad addiction indications
24 July 2018 – C4X Discovery Holdings plc (AIM:C4XD), a pioneering drug discovery company, is pleased to announce that C4X Discovery’s C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an oral Orexin-1 receptor antagonist, has demonstrated an excellent safety profile and preclinical efficacy in models of nicotine addiction.
Eva-Lotta Allan appointed Non-Executive Chairman of the Board
Board further strengthened with the appointment of Natalie Walter
4 July 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Eva-Lotta Allan and Natalie Walter have been appointed as Non-Executive Chairman of the Board and Non-Executive Director respectively, with immediate effect.
Scientists in Manchester are working on a drug to kill cravings.
After spending his youth hooked on drugs and alcohol, comedian Russell Brand came to a conclusion: addiction is a disease. For him it began with overeating as a child, and by the time he reached young adulthood, Brand had moved on to crack cocaine and heroin. Today, despite being clean for 15 years, the entertainer is adamant that he is still an addict — and that it is a medical condition.